The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
Clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with a post-treatment circulating tumor cell (CTC) of 0 vs CTC > 0: Post hoc analysis of COU-AA-301.
 
Howard I. Scher
Leadership - Asterias Biotherapeutics
Consulting or Advisory Role - Astellas Pharma; Blue Earth Diagnostics; Clovis Oncology; Elsevier; Ferring; Janssen Research & Development; Med IQ; Medivation; Merck; Roche; Sanofi; WIRB-Copernicus Group
Research Funding - Illumina (Inst); Innocrin Pharma (Inst); Janssen (Inst); Medivation (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ferring; Medivation; Roche; WIRB-Copernicus Group
 
Glenn Heller
No Relationships to Disclose
 
Margaret K. Yu
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Thian Kheoh
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Weimin Peng
No Relationships to Disclose
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex